Диссертация (1141255), страница 28
Текст из файла (страница 28)
–2017. – Т. 4. – № 3-4. – С. 46-56.82.Ягудина, Р.И. Современная методология анализа чувствительности вфармакоэкономических исследованиях / Р.И. Ягудина, А.Ю. Куликов, И.В.Новиков // Современная фармакоэкономика и фармакоэпидемиология – 2010.– Т. 3. – №4. – С. 8-12.83.Ягудина, Р.И. Эволюция ингаляционных систем доставки для лечениябронхиальной астмы / Р.И. Ягудина, Е.И. Макарова // Современнаяорганизация лекарственного обеспечения. – 2017 – Т.
4. – № 3–4. – С. 27-36.84.Aburuz, S. Assessment of impairment in health-related quality of life in patientswith difficult asthma: Psychometric performance of the Asthma Quality of LifeQuestionnaire / S. Aburuz, J. Gamble, L.G. Heaney // Respirology. – 2007. – Vol.12. – №2. – P.
227-233.85.Anderson, P.J. History of Aerosol Therapy : Liquid Nebulization to MDIs to DPIs/ P.J. Anderson // Respir. Care. – 2005. – Vol. 50. – № 9. – P. 1139-1149.86.Asher, M.I. International study of asthma and allergies in childhood (ISAAC):Rationale and methods / M.I. Asher [et al.] // Eur. Respir. J. – 1995. – Vol. 8. – №3. – P. 483-491.87.Asher, M.I. Worldwide variations in the prevalence of asthma symptoms: TheInternational Study of Asthma and Allergies in Childhood (ISAAC) / M.I. Asher[et al.] // Eur.
Respir. J. – 1998. – Vol. 12. – № 2. – P. 315-335.88.Asher, M.I. Worldwide time trends in the prevalence of symptoms of asthma,allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One andThree repeat multicountry cross-sectional surveys / M.I. Asher [et al.] // Lancet. –2006. – Vol. 368. – P. 733-743.89.Azouz, W. The Inhalation Characteristics of Patients When They Use DifferentDry Powder Inhalers / W. Azouz [et al.] // J. Aerosol Med. Pulm. Drug Deliv. –1822015. – Vol. – 28. – №1.
– P. 35-42.90.Björnsdõttir, U.S. Potential negative consequences of non-consented switch ofinhaled medications and devices in asthma patients / U.S. Björnsdõttir, S.Gizurarson, U. Sabale // Int. J. Clin. Pract. – 2013. – Vol. 67. – №9. – P. 904-910.91. Brazier, J. NICE DSU Technical Support Document 8: an Introduction To theMeasurement and Valuation of Health for Nice Submissions / J.
Brazier, L. Longworth– London: National Institute for Health and Care Excellence (NICE), 2011. – 29 p.92.Briggs, A.H. Cost-effectiveness of asthma control: An economic appraisal of theGOAL study / A.H Briggs [et al.] // Allergy Eur. J. Allergy Clin. Immunol. – 2006.– Vol. 61. – №5. – P. 531–536.93.Burström, K. Health-related quality of life by disease and socio-economic group inthe general population in Sweden / K.
Burström, M. Johannesson, F. Diderichsen// Health Policy (New. York). – 2001. – Vol. 55. – №1. – P. 51-69.94.Castro, M. Reslizumab for inadequately controlled asthma with elevated bloodeosinophil counts: results from two multicentre, parallel, double-blind,randomised, placebo-controlled, phase 3 trials / M. Castro [et al.] // Lancet Respir.Med. – 2015. – Vol.
3. – № 5. – P. 355-366.95.Chrystyn, H. Closer to an “Ideal Inhaler” with the Easyhaler / H. Chrystyn // Clin.Drug Investig. – 2006. – Vol. 26. – №4. – P. 175-183.96.Crompton, G. A brief history of inhaled asthma therapy over the last fifty years /G. Crompton // Prim. Care Respir. J. – 2006. – Vol. 15. – № 6. – P. 326-331.97. Doz, M. The association between asthma control, health care costs, and quality of life inFrance and Spain / M. Doz [et al.] // BMC Pulm. Med.
– 2013. – Vol. 13. – №15. – P. 2-10.98.Dubakiene, R. Clinically equivalent bronchodilatation achieved with formoteroldelivered via Easyhaler® and Aerolizer® / R. Dubakiene [et al.] // Respiration. –2006. – Vol. 73. – №4. – P. 441-448.99. EQ-5D. [Электронный ресурс] // Режим доступа: https://euroqol.org / Загл. с экрана.100.Gardenhire, D.S. A Guide to Aerosol Delivery Devices for RespiratoryTherapists, 3rd Edition / D.S. Gardenhire [et al.] – American Association forRespiratory Care, 2016. – 60 p.183101.Giraud, V.
Misuse of corticosteroid metered-dose inhaler is associated with decreasedasthma stability / V.Giraud, N. Roche // Eur. Respir. J. – 2002. – Vol. 19. – № 2. – P. 246-251.102.Global Initiative For Asthma (GINA). Global Strategy For Asthma Managementand Prevention. [Electronic resource] – Electronic text data.: Glob. Initiat. Asthma, 2018.– Available at: http://ginasthma.org/2018-gina-report-global-strat. – Загл. с экрана103.Global, regional, and national incidence, prevalence, and years lived withdisability for 328 diseases and injuries for 195 countries, 1990–2016: a systematicanalysis for the Global Burden of Disease Study 2016 / GBD 2016 Disease andInjury Incidence and Prevalence Collaborators // Lancet (London, England).
–2017. – Vol. 390. – P. 1211-1259.104.Haidl, P. Inhalation device requirements for patients’ inhalation maneuvers/ P. Haidl [et al.] // Respir. Med. – 2016. – Vol. 118. – P. 65-75.105.Hantulik, P. Usage and usability of one dry powder inhaler compared toother inhalers at therapy start: An open, non-interventional observational study inPoland and Germany / P. Hantulik [et al.] // Pneumonol. Alergol. – Pol. 2015. –Vol. 83. – № 5.
P. 365-377.106.Haughney, J. Achieving asthma control in practice: Understanding thereasons for poor control / J. Haughney [et al.] // Respir. Med. – 2008. – Vol. 102.– № 12. – P. 1681-1693.107.Haughney, J. Choosing inhaler devices for people with asthma: Currentknowledge and outstanding research needs / J. Haughney [et al.] // Respir. Med.CME. 2010.
– Vol. 3. – №3. – P. 125-131.108.Hillyer, E.V. Effectiveness of inhaler types for real-world asthmamanagement: retrospective observational study using the GPRD / E.V. Hillyer [etal.] // J. Asthma Allergy. – 2011. – № 4. – P. 37-47.109.Humbert, M. Benefits of omalizumab as add-on therapy in patients withsevere persistent asthma who are inadequately controlled despite best availabletherapy (GINA 2002 step 4 treatment): INNOVATE / M.
Humbert [et al.] //Allergy Eur. J. Allergy Clin. Immunol. – 2005. – Vol. 60. – № 3. – P. 309-316.110.Jia, H., Lubetkin, E.I. The impact of obesity on health-related quality-of-life184in the general adult US population / H. Jia, E.I Lubetkin // J. Public Health(Bangkok). 2005. – Vol. 27. -№ 2.
– P. 156–164.111.Juniper, E.F. Quality of life in adults and children with asthma and rhinitis./ E.F. Juniper // Allergy. –1997. – Vol. 52. – №10. – P. 971-977.112.Kelloway, J.S. A cost-effectiveness analysis of breath-actuated metered-dose inhalers. / J.S. Kelloway, R.
Wyatt // Manag Care Interface. – 1997. – Vol.10. – №9. – P. 99-107.113.Khaltaev, N. Chronic respiratory diseases and risk factors in 12 regions ofthe Russian Federation / N. Khaltaev, A.G. Chuchalin [et al.] // Int J Chron ObstructPulmon Dis – 2014. – № 9. – P. 963-974.114.King, C.
Switching patients from other inhaled corticosteroid devices to theEasyhaler: historical, matched-cohort study of real-life asthma patients / C. King,D. Price [et al.] // J. Asthma Allergy. – 2014. – № 7. – P. 31-51.115.Ko, Y. Self-reported chronic conditions and EQ‐5D index scores in the USadult population / Y.Ko, S.J.
Coons // Curr. Med. Res. Opin. – 2006. – Vol. 22. –№ 10. – P. 2065-2071.116.Kulikov, A. Budget impact analysis of budesonide in the treatment of asthmain adult population in Russian Federation / A. Kulikov, E. Makarova // Value inHealth – 2016. – Vol. 19 – № 3. – P. 113117.Kulikov, A. Budget impact analysis of formoterol Easyhaler in the treatmentof asthma in children in the Russian Federation / A. Kulikov, E. Kilimanova //Value in Health – 2015. – Vol. 18 – № 7. – P.
497118.Kulikov, A. Cost-effectiveness analysis of budesonid Easyhaler in thetreatment of asthma in children in the Russian Federation / A. Kulikov, E.Kilimanova // Value in Health – 2015. – Vol. 18 – № 7 – P. 501119.Kulikov, A. Cost-effectiveness analysis of formoterol for asthma treatmentin Russian Federation / A. Kulikov, E. Makarova // Value in Health – 2016.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
